This article was originally published in Start Up
By combining quantum chemistry and computing power, QuantumBio Inc. says it can model large macromolecules far better and more efficiently than currently available mechanics-based software. The company's tools promise better predictability of chemical and physical properties for virtual screening, QSAR, ADME/Tox, lead optimization and docking.
You may also be interested in...
Ask a head of R&D for a pharma or biotech to name the area where the need for new and better tools is greatest, and likely as not the answer will be predictive modeling of a drug's ADME/Tox profile. There's an abundance of sweet spots across the preclinical landscape for companies with better models and predictive tools.
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.